BGPT: Compare urinary HMG vs recombinant FSH and LH in IVF

Explore by Goal

Quick Analysis Plan Copied

Evidence from two retrospective IVF cohort studies suggests recombinant FSH alone retrieved more oocytes (+2.1) and produced more mature oocytes (+2.2) and cleaved embryos (+1.5) than regimens adding urinary-derived hMG, with similar clinical pregnancy rates (~6% difference, not significant), while recombinant FSH required fewer ampules than urinary FSH for equivalent outcomes . Both studies are retrospective, so randomized confirmation is required.

Long Analysis Plan

What the evidence shows: rFSH vs urinary HMG-containing regimens

In >1,300 GnRH-antagonist IVF cycles, adding hMG (urinary LH activity) to recombinant FSH did not improve outcomes: rec FSH alone retrieved ~2.1 more oocytes, ~2.2 more mature oocytes, ~1.9 more fertilized oocytes, and ~1.5 more cleaved embryos; clinical pregnancy rates were similar (rec FSH favored by ~6%, only approaching significance) .

A separate 476-cycle comparison found recombinant FSH needed fewer ampules and lower total dose than highly purified urinary FSH to reach follicular maturity, with similar pregnancy rates .

The LH 'window' complication

The story is not simply 'more LH is worse.' In 207 women on rFSH with GnRH-agonist down-regulation, mid-follicular LH showed an inverted-U relationship: both low (<0.5 IU/L; fertilization 45.9%) and high (>1.51 IU/L; fertilization 38.9%) LH were inferior to the 1.01–1.5 IU/L band (fertilization 63.7%), and FSH consumption fell inversely with LH (P < 0.002) .

A randomized HP-hMG vs rFSH trial (n=731, Ferring-funded) reported higher serum leptin with HP-hMG but no link between leptin and ovarian response or outcomes .

Critical limitations

Both gonadotropin-comparison cohorts are retrospective — selection bias and confounding (e.g., physicians assigning hMG to poorer-prognosis patients) could invert causality .
Industry funding (Ferring) in the HP-hMG trial warrants scrutiny of reporting direction .
An elevated FSH/LH ratio independently predicted poorer ovarian response (21% vs 34% pregnancy/cycle), suggesting baseline endocrine context — not just drug choice — drives outcomes .

What would change this conclusion: adequately powered randomized trials showing equal or superior oocyte yield with hMG-containing regimens, or subgroup evidence that LH supplementation benefits poor responders/low-LH patients specifically — the window data above make such subgroups biologically plausible.

Feedback:

Updated: September 24, 2026

Top Data Sources Export MCP

1. This study compares the efficacy of recombinant versus highly purified urinary follicle-stimulating hormone (FSH) preparations in controlled ovarian stimulation, finding that recombinant FSH is more efficient and requires fewer ampules for similar outcomes. [2001]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

2. This study evaluates the clinical outcomes of adding human menopausal gonadotropin (hMG) to recombinant follicle-stimulating hormone (rec FSH) in GnRH antagonist protocols for in vitro fertilization (IVF) across different age groups, revealing that rec FSH alone yields more oocytes and better embryo development without significant differences in pregnancy rates. [2005]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. This study investigates the hormonal interactions during the rat estrous cycle, revealing that the secretion rate of Follicle-Stimulating Hormone (FSH) is higher in the evening of proestrus compared to the morning, suggesting that both increased basal FSH release and maintained FSH responsiveness contribute to the secondary FSH surge. [1990]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

4. This study investigates whether an elevated FSH/LH ratio, despite normal hormonal levels, can predict poor ovarian response in patients undergoing IVF treatment, finding that such a ratio is indeed indicative of lower pregnancy rates and fewer oocytes retrieved. [2002]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

5. This study investigates the differential effects of acidic and less acidic isoforms of follicle-stimulating hormone (FSH) on ovarian follicular maturation and estrogen production in prepubertal lambs, demonstrating that the acidic isoform (C-FSH) is more effective than the less acidic form (N-FSH). [2002]

8QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

Key Insight

The 'LH is needed' vs 'LH is harmful' debate dissolves into a therapeutic-window problem: baseline FSH/LH ratio and mid-follicular LH predict response as strongly as drug choice, so trial-level averages mask patient-level benefit and harm.

Keep Exploring

Does recombinant LH versus urinary HMG-derived LH differ in clinical outcomes for poor ovarian responders in IVF?

How does the mid-follicular LH therapeutic window vary between GnRH agonist and antagonist protocols?

What role do FSH glycosylation isoforms play in explaining efficacy differences between urinary and recombinant gonadotropins?

DataGen

Generated scientific data; not direct experimental measurements.

Analysis Wizard

Building an analysis pipeline to compare oocyte yield, fertilization, and pregnancy outcomes between urinary HMG and recombinant FSH/LH protocols across the cited IVF studies, with bias-adjusted effect estimates.

Hypothesis Graveyard

'Adding LH always improves embryo quality' — falsified in unselected antagonist-protocol cohorts where hMG addition reduced oocyte, fertilization, and cleaved-embryo counts.

'More gonadotropin bioactivity equals more oocytes' — contradicted by the rFSH dose-efficiency finding and by the inverted-U LH response curve.

Potential Experiments

Stratify a prospective IVF cohort by day-8 LH (<0.5, 0.5–1.5, >1.5 IU/L) before randomizing to hMG addition vs placebo-LH; the oocyte-yield treatment-by-LH interaction directly tests the LH-window hypothesis with ~200 per stratum.

Quantify FSH isoform acidity (isoelectric focusing) in paired urinary-hMG and rFSH lots and regress lot isoform distribution on follicular E2 rise per 100 IU FSH across 50 cycles, separating LH-content effects from glycoform effects.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents industry-sponsored gonadotropin trials and may under-weight negative trials and non-English literature on urinary HMG.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Aggregated Evidence

Compile and compare specific findings across multiple studies into unified evidence records.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

What the evidence shows: rFSH vs urinary HMG-containing regimens

The LH 'window' complication

Critical limitations

Top Data Sources Export MCP

1. This study compares the efficacy of recombinant versus highly purified urinary follicle-stimulating hormone (FSH) preparations in controlled ovarian stimulation, finding that recombinant FSH is more efficient and requires fewer ampules for similar outcomes. [2001]

4. This study investigates whether an elevated FSH/LH ratio, despite normal hormonal levels, can predict poor ovarian response in patients undergoing IVF treatment, finding that such a ratio is indeed indicative of lower pregnancy rates and fewer oocytes retrieved. [2002]

9. This study developed a radioimmunoassay for inhibin to measure its plasma concentrations throughout the sheep oestrous cycle and after FSH infusion, revealing that FSH stimulates ovarian inhibin secretion but does not account for the fall in FSH during the follicular phase. [1989]

12. This study investigates the effects of bovine testicular extracts on plasma levels of FSH and LH in castrate male sheep, demonstrating that these extracts can selectively suppress FSH levels while LH levels tend to rise. [1976]

Ask a Follow-Up

Key Insight

The 'LH is needed' vs 'LH is harmful' debate dissolves into a therapeutic-window problem: baseline FSH/LH ratio and mid-follicular LH predict response as strongly as drug choice, so trial-level averages mask patient-level benefit and harm.

Keep Exploring

Does recombinant LH versus urinary HMG-derived LH differ in clinical outcomes for poor ovarian responders in IVF?

How does the mid-follicular LH therapeutic window vary between GnRH agonist and antagonist protocols?

What role do FSH glycosylation isoforms play in explaining efficacy differences between urinary and recombinant gonadotropins?

DataGen

Analysis Wizard

Building an analysis pipeline to compare oocyte yield, fertilization, and pregnancy outcomes between urinary HMG and recombinant FSH/LH protocols across the cited IVF studies, with bias-adjusted effect estimates.

Hypothesis Graveyard

'Adding LH always improves embryo quality' — falsified in unselected antagonist-protocol cohorts where hMG addition reduced oocyte, fertilization, and cleaved-embryo counts.

'More gonadotropin bioactivity equals more oocytes' — contradicted by the rFSH dose-efficiency finding and by the inverted-U LH response curve.

Potential Experiments

Stratify a prospective IVF cohort by day-8 LH (<0.5, 0.5–1.5, >1.5 IU/L) before randomizing to hMG addition vs placebo-LH; the oocyte-yield treatment-by-LH interaction directly tests the LH-window hypothesis with ~200 per stratum.

Quantify FSH isoform acidity (isoelectric focusing) in paired urinary-hMG and rFSH lots and regress lot isoform distribution on follicular E2 rise per 100 IU FSH across 50 cycles, separating LH-content effects from glycoform effects.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents industry-sponsored gonadotropin trials and may under-weight negative trials and non-English literature on urinary HMG.

Stay current without chasing every paper.

My BGPT

Trending

Aggregated Evidence

Compile and compare specific findings across multiple studies into unified evidence records.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

What the evidence shows: rFSH vs urinary HMG-containing regimens

The LH 'window' complication

Critical limitations

Top Data Sources ExportMCP

1. This study compares the efficacy of recombinant versus highly purified urinary follicle-stimulating hormone (FSH) preparations in controlled ovarian stimulation, finding that recombinant FSH is more efficient and requires fewer ampules for similar outcomes. [2001]

4. This study investigates whether an elevated FSH/LH ratio, despite normal hormonal levels, can predict poor ovarian response in patients undergoing IVF treatment, finding that such a ratio is indeed indicative of lower pregnancy rates and fewer oocytes retrieved. [2002]

9. This study developed a radioimmunoassay for inhibin to measure its plasma concentrations throughout the sheep oestrous cycle and after FSH infusion, revealing that FSH stimulates ovarian inhibin secretion but does not account for the fall in FSH during the follicular phase. [1989]

12. This study investigates the effects of bovine testicular extracts on plasma levels of FSH and LH in castrate male sheep, demonstrating that these extracts can selectively suppress FSH levels while LH levels tend to rise. [1976]

Ask a Follow-Up

Key Insight

The 'LH is needed' vs 'LH is harmful' debate dissolves into a therapeutic-window problem: baseline FSH/LH ratio and mid-follicular LH predict response as strongly as drug choice, so trial-level averages mask patient-level benefit and harm.

Keep Exploring

Does recombinant LH versus urinary HMG-derived LH differ in clinical outcomes for poor ovarian responders in IVF?

How does the mid-follicular LH therapeutic window vary between GnRH agonist and antagonist protocols?

What role do FSH glycosylation isoforms play in explaining efficacy differences between urinary and recombinant gonadotropins?

DataGen

Analysis Wizard

Building an analysis pipeline to compare oocyte yield, fertilization, and pregnancy outcomes between urinary HMG and recombinant FSH/LH protocols across the cited IVF studies, with bias-adjusted effect estimates.

Hypothesis Graveyard

'Adding LH always improves embryo quality' — falsified in unselected antagonist-protocol cohorts where hMG addition reduced oocyte, fertilization, and cleaved-embryo counts.

'More gonadotropin bioactivity equals more oocytes' — contradicted by the rFSH dose-efficiency finding and by the inverted-U LH response curve.

Potential Experiments

Stratify a prospective IVF cohort by day-8 LH (<0.5, 0.5–1.5, >1.5 IU/L) before randomizing to hMG addition vs placebo-LH; the oocyte-yield treatment-by-LH interaction directly tests the LH-window hypothesis with ~200 per stratum.

Quantify FSH isoform acidity (isoelectric focusing) in paired urinary-hMG and rFSH lots and regress lot isoform distribution on follicular E2 rise per 100 IU FSH across 50 cycles, separating LH-content effects from glycoform effects.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data over-represents industry-sponsored gonadotropin trials and may under-weight negative trials and non-English literature on urinary HMG.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP